Teva Pharmaceutical Industries Limited (NYSE:TEVA) to Post Q2 2025 Earnings of $0.57 Per Share, Zacks Research Forecasts

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Analysts at Zacks Research raised their Q2 2025 earnings per share estimates for shares of Teva Pharmaceutical Industries in a research note issued to investors on Wednesday, April 17th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.57 for the quarter, up from their prior forecast of $0.56. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.28 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q1 2026 earnings at $0.53 EPS and FY2026 earnings at $2.70 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.25. Teva Pharmaceutical Industries had a positive return on equity of 34.90% and a negative net margin of 3.33%. The business had revenue of $4.46 billion during the quarter, compared to analyst estimates of $3.97 billion.

Other equities research analysts also recently issued reports about the company. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 1st. Jefferies Financial Group raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and increased their price objective for the stock from $10.00 to $14.00 in a research note on Tuesday, January 23rd. The Goldman Sachs Group raised their price target on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a “neutral” rating in a research note on Monday, February 5th. Barclays raised their price target on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Finally, Piper Sandler raised Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $12.00 to $19.00 in a research note on Monday, February 12th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.78.

Teva Pharmaceutical Industries Stock Down 3.0 %

Shares of Teva Pharmaceutical Industries stock opened at $12.78 on Thursday. The stock has a 50-day moving average price of $13.47 and a 200 day moving average price of $11.22. The company has a market cap of $14.33 billion, a P/E ratio of -27.19, a P/E/G ratio of 1.57 and a beta of 1.05. The company has a current ratio of 1.02, a quick ratio of 0.69 and a debt-to-equity ratio of 2.23. Teva Pharmaceutical Industries has a 1 year low of $7.09 and a 1 year high of $14.47.

Institutional Trading of Teva Pharmaceutical Industries

Several institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its stake in Teva Pharmaceutical Industries by 3.7% in the first quarter. BlackRock Inc. now owns 41,648,716 shares of the company’s stock worth $391,081,000 after purchasing an additional 1,494,814 shares in the last quarter. Phoenix Holdings Ltd. increased its holdings in Teva Pharmaceutical Industries by 2.3% in the third quarter. Phoenix Holdings Ltd. now owns 34,481,692 shares of the company’s stock valued at $351,713,000 after purchasing an additional 778,282 shares during the last quarter. Lingotto Investment Management LLP increased its holdings in shares of Teva Pharmaceutical Industries by 1.8% in the fourth quarter. Lingotto Investment Management LLP now owns 34,457,656 shares of the company’s stock worth $359,738,000 after acquiring an additional 607,800 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of Teva Pharmaceutical Industries by 7.1% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 32,804,131 shares of the company’s stock worth $342,788,000 after acquiring an additional 2,188,212 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 6.9% during the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,919,540 shares of the company’s stock worth $301,920,000 after buying an additional 1,860,000 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Activity

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 31,766 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $12.37, for a total value of $392,945.42. Following the sale, the chief accounting officer now owns 10,676 shares of the company’s stock, valued at approximately $132,062.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Mark Sabag sold 100,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the sale, the executive vice president now owns 382,590 shares of the company’s stock, valued at approximately $5,172,616.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Amir Weiss sold 31,766 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $12.37, for a total value of $392,945.42. Following the sale, the chief accounting officer now directly owns 10,676 shares in the company, valued at approximately $132,062.12. The disclosure for this sale can be found here. In the last quarter, insiders have sold 390,738 shares of company stock valued at $5,132,766. Insiders own 0.62% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.